Table II.

Post-treatment changes in International Prostate Symptom Score (IPSS; up to 60 months of follow-up).

Increase in post-treatment IPSS
Baseline IPSS	N*	No. of patients with > 5-point increase at any point after treatment (%)	No. of patients with > 5-point increase at last follow-up (%)	No. of patients with ≥ 5-point increase resolved at last follow-up (%)
< 15	137	62 (45.2%)	29 (21.2%)	33 (24.1%)
15–25	33	4 (12.1%)	1 (3.0%)	3 (9.1%)
Total	170	66 (38.8%)	30 (17.6%)	36 (21.2%)
Decrease in post-treatment IPSS
Baseline IPSS	N	No. of patients with > 5-point decrease at any point after treatment (%)	No. of patients with > 5-point decrease at last follow-up (%)	No. of patients with ≥ 5-point decrease in IPSS no longer present at last follow-up (%)
< 15	89**	35 (39.3%)	20 (22.5%)	15 (16.9%)
15–25	33	29 (87.9%)	18 (54.5%)	11 (33.3%)
Total	122	64 (52.5%)	38 (31.1%)	26 (21.3%)

*One patient died during treatment, leaving 170 available for follow-up analysis.

**48 patients of the 137 with IPSS < 15 had baseline. IPSS < 5 and thus could not be assessed for a decrease in IPSS of ≥ 5.